Generic Name: ivosidenib Brand Name: TIBSOVO
TIBSOVO (ivosidenib tablets) is used to treat acute myeloid leukemia (AML).

What ivosidenib is and used for?

ivosidenib, sold under the brand name TIBSOVO, is an anti-cancer drug. It acts as an inhibitor of FLT3, hence it is a tyrosine kinase inhibitor. It was developed by Astellas Pharma. In April 2018, Astellas filed a new drug application with the Food and Drug Administration for ivosidenib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML).

In November 2018, the FDA approved ivosidenib for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ivosidenib was granted orphan drug status by the U.S. FDA, the European Commission (EC) and the Japan Ministry of Health, Labor and Welfare, for some AML patients. ivosidenib was approved for medical use in Australia in March 2020.

How can 1 go about obtaining TIBSOVO Tablets?

If TIBSOVO (ivosidenib Tablets) are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

News / Updates